UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Blood, 2016-06, Vol.127 (26), p.3360-3368

2016

Volltextzugriff (PDF)

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Blood, 2012-05, Vol.119 (19), p.4375-4382

2012

Volltextzugriff (PDF)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

British journal of haematology, 2019-05, Vol.185 (3), p.492-502

2019

Volltextzugriff (PDF)

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes

Clinical lymphoma, myeloma and leukemia, 2017-09, Vol.17 (9), p.575-583.e2

2017

Volltextzugriff (PDF)

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

American journal of hematology, 2018-10, Vol.93 (10), p.1199-1206

2018

Volltextzugriff (PDF)

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2016-07, Vol.34 (21), p.2484-2492

2016

Volltextzugriff (PDF)

Recognition of early mortality in multiple myeloma by a prediction matrix

American journal of hematology, 2017-09, Vol.92 (9), p.915-923

2017

Volltextzugriff (PDF)

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States

Clinical lymphoma, myeloma and leukemia, 2018-02, Vol.18 (2), p.152-160

2018

Volltextzugriff (PDF)

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma : A phase III multicenter randomized trial

Cancer, 2006-02, Vol.106 (4), p.848-858

2006

Volltextzugriff (PDF)

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry

Blood cancer journal (New York), 2021-07, Vol.11 (7), p.134-134, Article 134

2021

Volltextzugriff (PDF)

Connect MM Registry as a national reference for United States multiple myeloma patients

Cancer medicine (Malden, MA), 2020-01, Vol.9 (1), p.35-42

2020

Volltextzugriff (PDF)

Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide

Leukemia & lymphoma, 2016-09, Vol.57 (9), p.2228-2231

2016

Volltextzugriff (PDF)

Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics

Clinical lymphoma, myeloma and leukemia, 2015-06, Vol.15 (6), p.368-376

2015

Volltextzugriff (PDF)

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

British journal of haematology, 2004-05, Vol.125 (4), p.470-476

2004

Volltextzugriff (PDF)

Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study

Clinical therapeutics, 2019-05, Vol.41 (5), p.866-881.e7

2019

Volltextzugriff (PDF)

Clinical Benefits and Economic Analysis of Pegylated Liposomal Doxorubicin/Vincristine/Dexamethasone Versus Doxorubicin/Vincristine/Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Clinical lymphoma & myeloma, 2007-04, Vol.7, p.S150-S155

2007

Volltextzugriff (PDF)

Percutaneous treatment of long bone nonunions: the use of autologous bone marrow and allograft bone matrix

Orthopedics (Thorofare, N.J.), 2003-05, Vol.26 (5 Suppl), p.s549

2003

Volltextzugriff (PDF)

The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry

Clinical lymphoma, myeloma and leukemia, 2024-10, Vol.24 (10), p.e336-e343

2024

Volltextzugriff (PDF)

Comparison of proximal isovelocity surface area method with pressure half-time and planimetry in evaluation of mitral stenosis

Journal of the American College of Cardiology, 1995-08, Vol.26 (2), p.458-465

1995

Volltextzugriff (PDF)

Operational definition of normal sinus heart rate

The American journal of cardiology, 1992-05, Vol.69 (14), p.1245-1246

1992

Volltextzugriff (PDF)

Comparison with radionuclide angiography of two new geometric and four nongeometric models for echocardiographic estimation of left ventricular ejection fraction using segmental wall motion scoring

The American journal of cardiology, 1990-06, Vol.65 (22), p.1485-1490

1990

Volltextzugriff (PDF)

Malignant melanoma--profile of an epidemic

The Western journal of medicine, 1988-07, Vol.149 (1), p.43

1988

Volltextzugriff (PDF)

Postinfarction septal aneurysm with delayed formation of left-to-right shunt

The American heart journal, 1991-07, Vol.122 (1), p.226-230

1991

Volltextzugriff (PDF)

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

The New England journal of medicine, 2010-07, Vol.363 (5), p.411-422

2010

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

ThemaAged, 80 And Over

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

Aged
(33)
Humans
(33)
Male
(32)
Female
(31)
Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Middle Aged
(30)
Adult
(26)
Oncology
(14)
Hematology
(13)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Multiple Myeloma - Drug Therapy
(10)
Treatment Outcome
(10)
Multiple Myeloma
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(6)
Dexamethasone - Administration & Dosage
(6)
Multiple Myeloma - Mortality
(6)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Recognition of early mortality in multiple myeloma by a prediction matrix

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma : A phase III multicenter randomized trial

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry

Connect MM Registry as a national reference for United States multiple myeloma patients

Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide

Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Clinical Benefits and Economic Analysis of Pegylated Liposomal Doxorubicin/Vincristine/Dexamethasone Versus Doxorubicin/Vincristine/Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Percutaneous treatment of long bone nonunions: the use of autologous bone marrow and allograft bone matrix

The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry

Comparison of proximal isovelocity surface area method with pressure half-time and planimetry in evaluation of mitral stenosis

Operational definition of normal sinus heart rate

Comparison with radionuclide angiography of two new geometric and four nongeometric models for echocardiographic estimation of left ventricular ejection fraction using segmental wall motion scoring

Malignant melanoma--profile of an epidemic

Postinfarction septal aneurysm with delayed formation of left-to-right shunt

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Aktive Filter

Suchergebnisse filtern